Dr. Piotrowska is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
55 Fruit St
Boston, MA 02114Phone+1 617-724-4000
Education & Training
- Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 2012 - 2016
- Brigham and Women's HospitalResidency, Internal Medicine, 2008 - 2011
- Yale School of MedicineClass of 2008
Certifications & Licensure
- MA State Medical License 2010 - 2025
- American Board of Internal Medicine Medical Oncology
Clinical Trials
- Rapid Plasma Genotyping For Early Initiation Of Erlotinib In EGFR Mutant Lung Cancer Start of enrollment: 2016 Jun 01
- A Study of EGF816 and Gefitinib in TKI-naïve EGFR-mutant Non-Small Cell Lung Cancer Start of enrollment: 2017 Oct 31
- A Phase 2 Study of Osimertinib in Combination With Selumetinib in EGFR Inhibitor naïve Advanced EGFR Mutant Lung Cancer Start of enrollment: 2018 Jan 31
- Join now to see all
Publications & Presentations
PubMed
- Phase 2 Trial of Consolidative Stereotactic Body Radiation Therapy in Patients With Metastatic Oncogene-driven Non-small Cell Lung Carcinoma Treated With Tyrosine Kina...Florence K Keane, Beow Y Yeap, Melin J Khandekar, Jessica J Lin, Ibiayi Dagogo-Jack
International Journal of Radiation Oncology, Biology, Physics. 2025-03-15 - Access to Diagnostics and Treatment for People With Metastatic EGFR-Positive NSCLC: Lessons From Project PRIORITY.Jill Feldman, Ivy Elkins, Zofia Piotrowska, Bellinda L King-Kallimanis, Tendai Chihuri
JTO Clinical and Research Reports. 2025-03-01 - 3 citationsPhase I/II Investigator-Initiated Study of Olaparib and Temozolomide in SCLC: Final Analysis and CNS Outcomes.Catherine B Meador, Subba R Digumarthy, Beow Y Yeap, Yin P Hung, Mari Mino-Kenudson
Clinical Cancer Research. 2025-01-06
Journal Articles
- Oxford University Press Has Registered This DOI Pre-PublicationR S Heist, Z Piotrowska, C G Azzoli, A T Shaw, I T Lennes, L V Sequist, J F Gainor, Oxford University Press
- EGFR Exon 20 Insertion Mutations Display Sensitivity to Hsp90 Inhibition in Preclinical Models and Lung AdenocarcinomasLecia V Sequist, Zofia Piotrowska, Clinical Cancer Research
Press Mentions
- Withdrawn NSCLC Drug: Was Ambitious Phase 3 Trial Design to Blame?March 5th, 2025
- Medical Mysteries: She Went Undiagnosed Until Almost Too LateMay 25th, 2024
- Highlights at ASCO22: Advancements in NSCLC TherapiesJune 24th, 2022
- Join now to see all
Grant Support
- Non-genomic resistance mechanisms in EGFR-mutant lung cancerMASSACHUSETTS GENERAL HOSPITAL2009–2027
Other Languages
- French, Polish
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: